INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

INmune Bio signed a Master Services Agreement with Uniphar to provide international access, distribution and commercialization infrastructure for Ebstrocel, its allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa. Initial focus is named-patient access in selected European and MENA markets, allowing physicians to request the therapy for individual patients before local marketing approval, with scope to expand by mutual agreement. The company frames the deal as a capital-efficient path that avoids building country-by-country capabilities internally, ahead of planned MAA filings with the UK MHRA in 2026 and EU EMA in 2027.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.